Annual report
4671.TEDINET S100OCZP
Period2021-04-01 → 2022-03-31
Filed2022-06-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥43.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥43.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥44.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥46.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥2.6bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.9bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥941m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.9bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥653m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥37.1bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥32.0bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥32.1bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥32.7bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥16.6bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥20.5bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.9bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥19.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥19.1bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.6bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.4bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.3bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥615m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥845m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥41m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178.61 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.87 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.8 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.12 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥177.54 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.06 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.44 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥155.65 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,237.14 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,966.43 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,776.01 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,725.03 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,745.4 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.0% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.8% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.2% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,179 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 1,200 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 1,249 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 1,348 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 1,377 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥3.8bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.9bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥2.4bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.1bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥2.0bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥2.7bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥722m | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.8bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥806m | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥742m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥1.0bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.1bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥990m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥24.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥24.2bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥20.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.3bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.2bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥6.2bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥20.1bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥18.0bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥17.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥17.4bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥15.0bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥8.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥9.7bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥254.07 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥96.55 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.11 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥281.59 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.1 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥252.56 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥95.97 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥117.29 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥279.93 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥90.82 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥64 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥44 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,914.28 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,726.33 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,621.07 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,574.26 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,371.3 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 82.4% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.9% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.0% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 11,280,177 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 2 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 2 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 4 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 5 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥1.7bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥198m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥16m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥21.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥403m |
| Clinical Testing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥580m |
| Clinical Testing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥628m |
| Clinical Testing Businessreportable segment | employees | at 2022-03-31 | 762 pure |
| Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥33.7bn |
| Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥33.7bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥15m |
| Clinical Testing Businessreportable segment | segment assets | at 2022-03-31 | ¥13.1bn |
| Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥4.9bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥204m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥115m |
| Dispensing Pharmacy Businessreportable segment | employees | at 2022-03-31 | 393 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2022-03-31 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥784m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥744m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥50.0bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥50.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥16m |
| —segment total | segment assets | at 2022-03-31 | ¥18.7bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.9bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥1.2bn |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥184m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥16m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥16m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥20.9bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥328m |
| Clinical Testing Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥310m |
| Clinical Testing Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥630m |
| Clinical Testing Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥27.2bn |
| Clinical Testing Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥27.2bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥15m |
| Clinical Testing Businessreportable segment | segment assets | at 2021-03-31 | ¥11.0bn |
| Clinical Testing Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.0bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥30m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥121m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2021-03-31 | ¥5.2bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥968m |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥341m |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥752m |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥43.6bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥43.6bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥16m |
| —segment total | segment assets | at 2021-03-31 | ¥16.2bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,546
| Item | Context | Value | Unit |
|---|---|---|---|
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.962 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.266 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.287 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.501 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.135 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.052 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.928 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.292 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.287 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 762 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 1215 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 393 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 177 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 24 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 1 | |
| Number of employees | CurrentYearInstant | 1179 | |
| Average number of temporary workers | CurrentYearInstant | 1393 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 3 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 51.3 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 30.2 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7666751 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 3 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 1 | |
| Research and development expenses research and development activities | CurrentYearDuration | 300000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 2505000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 580000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 201000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 11280177 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 20 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 23 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 87 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 64 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 9 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 7093 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 7296 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 27854 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 1585 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 27864 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 6030 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 109 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 49116 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 112558 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 24377 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |